𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Influence of repeated administration of cimetidine on the pharmacokinetics and pharmacodynamics of adinazolam in healthy subjects

✍ Scribed by R. Hulhoven; J. P. Desager; S. Cox; C. Harvengt

Publisher
Springer
Year
1988
Tongue
English
Weight
696 KB
Volume
35
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The lack of effect of smoking on the pha
The lack of effect of smoking on the pharmacokinetics and pharmacodynamics of adinazolam and N-demethyladinazolam
✍ J. H. Chambers; J. C. Fleishaker πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 533 KB

The pharmacokinetics and pharmacodynamics of adinazolam and Ndemethyladinazolam (NDMAD) were evaluated in twelve healthy non-smokers (NS) and twelve smokers (S, 2 20 cigarettedday) following a single 60 mg dose of adinazolam mesylate sustainedrelease tablets in an open-label, parallel-group design.

Comparative pharmacokinetics of midazola
Comparative pharmacokinetics of midazolam and loprazolam in healthy subjects after oral administration
✍ R. Jochemsen; P. A. Van Rijn; T. G. M. Hazelzet; C. J. Van Boxtel; D. D. Breimer πŸ“‚ Article πŸ“… 1986 πŸ› John Wiley and Sons 🌐 English βš– 397 KB πŸ‘ 1 views

The pharmacokinetics of oral midazolam (Dormicum@, 15 mg) and loprazolam (Dormonoct@, 1 mg) were studied in eight healthy young volunteers in a cross-over design. Plasma concentrations of midazolam were measured with a gas chromatographic method and loprazolam concentrations were determined by a rad

Pharmacokinetics and pharmacodynamics of
Pharmacokinetics and pharmacodynamics of a slow-release formulation of diltiazem after the administration of a single and repeated doses to healthy volunteers
✍ M. Lefebvre; Y. Lacasse; J. SpΓ©nard; D. Geadah; R. Moisan; D. Gossard; H. Landri πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 782 KB

Diltiazem is a calcium antagonist used in angina pectoris and hypertension. There is little information concerning the slow-release (SR) formulation in the literature. The pharmacokinetics of diltiazem SR (120 mg) have been assessed over a 36 h period in healthy volunteers after single-(SD) and mult